NEW YORK, N.Y. — October 12, 2026 — Longevity biotech startup Longevica Therapeutics has announced the formation of its Scientific Advisory Board (SAB) to translate data from a landmark $13 million, 16,000-subject in vivo mammalian longevity screen into commercial drug pipelines. The advisory team will guide Longevica’s AI-driven drug discovery engine, targeting healthspan extension in companion animals alongside human-adjacent therapeutic candidates.
Translating In Vivo Phenomics Through Machine Learning
Unlike platforms reliant solely on in vitro or single-cell models, Longevica’s platform is built on longitudinal data tracking over 60 chemical compounds that demonstrated statistically significant lifespan extension (ranging from 10% to 22%) in mammalian models.
Strategic Focus on Companion Animal Healthspan
The company’s dual-track commercial strategy leverages veterinary therapeutics as both a high-growth market and an accelerated real-world validation pathway for human translation:
-
Multidisciplinary Leadership: The newly appointed board includes bioinformatics pioneers, pharmacologists, and clinical trial strategists—including Dr. Steven Garan (UC Berkeley), Dr. Alexey Ryazanov (Rutgers University), and Dr. Adrian Salic (Harvard Medical School).
-
Companion Animal Formulations: Translating non-toxic, small-molecule formulations designed to preserve mobility, cognitive function, and metabolic vitality in aging dogs and cats.
-
Accelerated Clinical Execution: By utilizing companion animal clinical trials, Longevica aims to achieve rapid safety and efficacy readouts under real-world environmental conditions, bypassing long mammalian trial bottlenecks.
